EXELIXIS, INC.
EXELNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY26 | FY25 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $987.5M | $967.8M |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $110.1M | $369.5M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $111.8M | $321.0M |
| Total assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.14B | $1.89B |
| Total liabilities | $683.1M | $703.5M | $678.4M | $583.1M | $258.2M | $199.7M |
| Equity | $2.16B | $2.24B | $2.26B | $2.49B | $1.88B | $1.69B |
| EPS (diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.35 | $1.02 |
| Shares out. | 259.7M | 279.9M | 324.1M | 319.4M | 312.0M | 305.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2026- Operating margin
- 37.6%
- Net margin
- 33.7%
- Return on equity
- 36.2%
- Return on assets
- 27.5%
- Return on capital (ROCE)
- 35.8%
- Liabilities / assets
- 24.0%
- Debt / equity
- 0.32×
- Book value / share
- $8.32
- Revenue growth (YoY)
- 7.0%
- Net income growth (YoY)
- 50.1%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2026- Altman Z″ (distress)
- 7.69safe
- Accruals / assets
- −3.6%clean
- Beneish M-Score
- -2.59normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 7 good- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- COMETRIQNov 29, 2012
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 4Active Not Recruitingreadout ~2020-07-15A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
- Phase 3Active Not Recruitingreadout ~2020-08-19A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- Phase 3Active Not Recruitingreadout ~2021-11-30Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
- Phase 3Active Not Recruitingreadout ~2022-01-31Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Phase 1Active Not Recruitingreadout ~2023-02-21Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase 3Active Not Recruitingreadout ~2024-04-19Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- Phase 3Active Not Recruitingreadout ~2025-07Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Phase 1Recruitingreadout ~2025-12Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Aqr Capital Management LlcPassive (13G)Feb 13, 2026
- Farallon Capital Partners, L.P.Activist (13D)Jan 5, 2026
- Blackrock, Inc.Passive (13G)Apr 28, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 30.3M | 9.2 | +0.9% |
| Apr 30, 2026 | 30.0M | 12.6 | +6.0% |
| Apr 15, 2026 | 28.3M | 13.1 | +3.8% |
| Mar 31, 2026 | 27.3M | 11.0 | +3.5% |
| Mar 13, 2026 | 26.4M | 7.4 | +0.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 29, 2026
- Results of operations · Other material eventMay 5, 2026
- Results of operationsFeb 10, 2026
- Results of operationsJan 12, 2026
- Director / officer change · Other material eventNov 7, 2025
- Results of operations · Other material eventNov 4, 2025
- Director / officer changeAug 29, 2025
- Results of operationsJul 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.